Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 33, Issue 8, 2014, Pages 1311-1322

  Batirel, A ^a   Balkan, I I ^b   Karabay, O ^c   Agalar, C ^d   Akalin, S ^e   Alici, O ^d   Alp, E ^f   Altay, F A ^g   Altin, N ^h   Arslan, F ⁱ   Aslan, T ^j   Bekiroglu, N ^k   Cesur, S ^h   Celik, A D ^l   Dogan, M ^m   Durdu, B ⁿ   Duygu, F ^o   Engin, A ^p   Engin, D O ^q   Gonen, I ^r   Guclu, E ^c   Guven, T ^s   Hatipoglu, C A ^t   Hosoglu, S ^u   Karahocagil, M K ^v   Kilic, A U ^f   Ormen, B ^s   Ozdemir, D ^w   Ozer, S ^a   Oztoprak, N ^x   Sezak, N ^w   Turhan, V ^y   Turker, N ^w   Yilmaz, H ^z   more..

^a DR LUTFI KIRDAR KARTAL EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c SAKARYA UNIVERSITY   (Turkey)

^d Fatih Sultan Mehmet Teaching and Research Hospital   (Turkey)

^e PAMUKKALE UNIVERSITY   (Turkey)

^f ERCIYES UNIVERSITY   (Turkey)

^g Diskapi Education and Research Hospital   (Turkey)

^h Etlik Education and Research Hospital   (Turkey)

ⁱ ISTANBUL MEDIPOL UNIVERSITY   (Turkey)

^j Bezmi Alem University   (Turkey)

^k MARMARA UNIVERSITY   (Turkey)

^l TRAKYA UNIVERSITY   (Turkey)

^m NAMIK KEMAL UNIVERSITY   (Turkey)

ⁿ Bakirkoy Sadi Konuk Education and Research Hospital   (Turkey)

^o GAZIOSMANPASA UNIVERSITY   (Turkey)

^p CUMHURIYET UNIVERSITY   (Turkey)

^q HAYDARPASA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^r SULEYMAN DEMIREL UNIVERSITY   (Turkey)

^s ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^t ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^u DICLE UNIVERSITY   (Turkey)

^v YUZUNCU YIL UNIVERSITY   (Turkey)

^w DUZCE UNIVERSITY   (Turkey)

^x Orthopaedics and Traumatology Clinic   (Turkey)

^y GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

^z ONDOKUZ MAYIS UNIVERSITY   (Turkey)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CARBAPENEM; COLISTIN; DORIPENEM; GENTAMICIN; IMIPENEM; MEROPENEM; NETILMICIN; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; SULBACTAM; SULTAMICILLIN; TIGECYCLINE; CARBAPENEM DERIVATIVE;

ACINETOBACTER BAUMANNII; ADULT; APACHE; ARTICLE; BLOODSTREAM INFECTION; CHARLSON COMORBIDITY INDEX; CONCURRENT INFECTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; ERADICATION THERAPY; FEMALE; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PITT BACTEREMIA SCORE; PRIORITY JOURNAL; PROPENSITY SCORE; RISK FACTOR; SCORING SYSTEM; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; ACINETOBACTER INFECTIONS; AGED; BACTEREMIA; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; MULTICENTER STUDY; MULTIDRUG RESISTANCE; RETROSPECTIVE STUDY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGED; BACTEREMIA; CARBAPENEMS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LENGTH OF STAY; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SULBACTAM; TREATMENT OUTCOME;

EID: 84903819291     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-014-2070-6     Document Type: Article

References (44)

1. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18(3):268-281
2. Vila J, Pachón J (2008) Therapeutic options for Acinetobacter baumannii infections. Expert Opin Pharmacother 9(4):587-599 (Pubitemid 351425386)
3. Falagas ME, Karveli EA, Siempos II, Vardakas KZ (2008) Acinetobacter infections: a growing threat for critically ill patients. Epidemiol Infect 136(8):1009-1019 (Pubitemid 351982921)
4. Erbay A, Idil A, Gözel MG, Mumcuoǧlu I, Balaban N (2009) Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections. Int J Antimicrob Agents 34(6):575-579
5. Kim YJ, Kim SI, Hong KW, Kim YR, Park YJ, Kang MW (2012) Risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia: impact of appropriate antimicrobial therapy. J Korean Med Sci 27(5):471-475
6. Kallel H, Bahloul M, Hergafi L, Akrout M, Ketata W, Chelly H, Hamida CB, Rekik N, Hammami A, Bouaziz M (2006) Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int J Antimicrob Agents 28(4):366-369 (Pubitemid 44403003)
7. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, Liolios L (2006) Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 50(9):2946-2950 (Pubitemid 44396396)
8. Rahal JJ (2006) Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 43(Suppl 2):S95-S99
9. Petrosillo N, Chinello P, Proietti MF, Cecchini L, Masala M, Franchi C, Venditti M, Esposito S, Nicastri E (2005) Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events. Clin Microbiol Infect 11(8):682-683 (Pubitemid 41051389)
10. Pantopoulou A, Giamarellos-Bourboulis EJ, Raftogannis M, Tsaganos T, Dontas I, Koutoukas P, Baziaka F, Giamarellou H, Perrea D (2007) Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin. Int J Antimicrob Agents 29(1):51-55 (Pubitemid 44959789)
11. Montero A, Ariza J, Corbella X, Doménech A, Cabellos C, Ayats J, Tubau F, Borraz C, Gudiol F (2004) Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 54(6):1085-1091 (Pubitemid 40136746)
12. Saballs M, Pujol M, Tubau F, Peña C, Montero A, Domínguez MA, Gudiol F, Ariza J (2006) Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 58(3):697-700 (Pubitemid 44288144)
13. Rodríguez-Hernández MJ, Pachón J, Pichardo C, Cuberos L, Ibáñez-Martínez J, García-Curiel A, Caballero FJ, Moreno I, Jiménez-Mejías ME (2000) Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia. J Antimicrob Chemother 45(4):493-501
14. Bernabeu-Wittel M, Pichardo C, García-Curiel A, Pachón-Ibáñez ME, Ibáñez-Martínez J, Jiménez-Mejías ME, Pachón J (2005) Pharmacokinetic/ pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia. Clin Microbiol Infect 11(4):319-325 (Pubitemid 40443839)
15. Haddad FA, Van Horn K, Carbonaro C, Aguero-Rosenfeld M, Wormser GP (2005) Evaluation of antibiotic combinations against multidrug-resistant Acinetobacter baumannii using the E-test. Eur J Clin Microbiol Infect Dis 24(8):577-579 (Pubitemid 41414014)
16. Ko WC, Lee HC, Chiang SR, Yan JJ, Wu JJ, Lu CL, Chuang YC (2004) In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain. J Antimicrob Chemother 53(2):393-395
17. Kiffer CR, Sampaio JL, Sinto S, Oplustil CP, Koga PC, Arruda AC, Turner PJ, Mendes C (2005) In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii. Diagn Microbiol Infect Dis 52(4):317-322 (Pubitemid 41297570)
18. Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hammer SM, Kubin CJ (2004) Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother 54(2):566-569 (Pubitemid 39177490)
19. Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME (2005) Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 49(8):3136-3146 (Pubitemid 41060551)
20. Bassetti M, Repetto E, Righi E, Boni S, Diverio M, Molinari MP, Mussap M, Artioli S, Ansaldi F, Durando P, Orengo G, Bobbio Pallavicini F, Viscoli C (2008) Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 61(2):417-420
21. Horan TC, Andrus M, Dudeck MA (2008) CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36(5):309-332 (Pubitemid 351763841)
22. Chow JW, Yu VL (1999) Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int J Antimicrob Agents 11(1):7-12 (Pubitemid 29067411)
23. Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHE II: a severity of disease classification system. Crit Care Med 13(10):818-829 (Pubitemid 15250137)
24. Chen SJ, Chao TF, Chiang MC, Kuo SC, Chen LY, Yin T, Chen TL, Fung CP (2011) Prediction of patient outcome from Acinetobacter baumannii bacteremia with Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation (APACHE) II scores. Intern Med 50(8):871-877
25. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373-383 (Pubitemid 17055592)
26. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P; Acute Dialysis Quality Initiative workgroup (2004) Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8(4):R204-R212
27. Spapen H, Jacobs R, Van Gorp V, Troubleyn J, Honoré PM (2011) Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care 1(1):14
28. Falagas ME, Koletsi PK, Bliziotis IA (2006) The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 55(Pt 12):1619-1629 (Pubitemid 44902023)
29. Fowler RA, Flavin KE, Barr J, Weinacker AB, Parsonnet J, Gould MK (2003) Variability in antibiotic prescribing patterns and outcomes in patients with clinically suspected ventilator-associated pneumonia. Chest 123(3):835-844 (Pubitemid 36315501)
30. Vouillamoz J, Moreillon P, Giddey M, Entenza JM (2008) In vitro activities of tigecycline combined with other antimicrobials against multiresistant gram-positive and gram-negative pathogens. J Antimicrob Chemother 61(2):371-374
31. Principe L, D'Arezzo S, Capone A, Petrosillo N, Visca P (2009) In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. Ann Clin Microbiol Antimicrob 8:18
32. Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthaiou DK, Karageorgopoulos DE, Kapaskelis A, Nikita D, Michalopoulos A (2010) Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 35(2):194-199
33. Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, Bassetti M, Malacarne P, Petrosillo N, Galdieri N, Mocavero P, Corcione A, Viscoli C, Zarrilli R, Gallo C, Utili R (2013) Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 57(3):349-358
34. Pogue JM, Kaye KS (2013) Is there really no benefit to combination therapy with colistin? Expert Rev Anti Infect Ther 11(9):881-884
35. Gauthier TP (2013) Editorial commentary: rifampicin plus colistin in the era of extensively drug-resistant Acinetobacter baumannii infections. Clin Infect Dis 57(3):359-361
36. Song JY, Cheong HJ, Choi WS, Heo JY, Noh JY, Kim WJ (2011) Clinical and microbiological characterization of carbapenem-resistant Acinetobacter baumannii bloodstream infections. J Med Microbiol 60(Pt 5):605-611
37. Kuo SC, Lee YT, Yang SP, Chiang MC, Lin YT, Tseng FC, Chen TL, Fung CP (2013) Evaluation of the effect of appropriate antimicrobial therapy on mortality associated with Acinetobacter nosocomialis bacteraemia. Clin Microbiol Infect 19(7):634-639
38. Ogutlu A, Guclu E, Karabay O, Utku AC, Tuna N, Yahyaoglu M (2014) Effects of Carbapenem consumption on the prevalence of Acinetobacter infection in intensive care unit patients. Ann Clin Microbiol Antimicrob 13(1):7
39. Deveci A, Coban AY, Acicbe O, Tanyel E, Yaman G, Durupinar B (2012) In vitro effects of sulbactam combinations with different antibiotic groups against clinical Acinetobacter baumannii isolates. J Chemother 24(5):247-252
40. Cikman A, Ceylan MR, Parlak M, Karahocagil MK, Berktaş M (2013) Evaluation of colistin-ampicillin/sulbactam combination efficacy in imipenem-resistant Acinetobacter baumannii strains. Mikrobiyol Bul 47(1):147-151
41. Dizbay M, Tozlu DK, Cirak MY, Isik Y, Ozdemir K, Arman D (2010) In vitro synergistic activity of tigecycline and colistin against XDR-Acinetobacter baumannii. J Antibiot (Tokyo) 63(2):51-53
42. Michalopoulos A, Falagas ME, Karatza DC, Alexandropoulou P, Papadakis E, Gregorakos L, Chalevelakis G, Pappas G (2011) Epidemiologic, clinical characteristics, and risk factors for adverse outcome in multiresistant gram-negative primary bacteremia of critically ill patients. Am J Infect Control 39(5):396-400
43. Tseng YC, Wang JT, Wu FL, Chen YC, Chie WC, Chang SC (2007) Prognosis of adult patients with bacteremia caused by extensively resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 59(2):181-190
44. Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J, Cosgrove SE, Anderson A, Carnell J, Jernigan DB, Kleinbaum DG, Perl TM, Standiford HC, Srinivasan A (2007) Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 13(1):97-103 (Pubitemid 46057843)